Related Experiment Videos
Short-acting beta-agonist research: a perspective. 1997.
Canadian Respiratory Journal
|November 6, 2001
Summary
Frequent use of the asthma medication fenoterol was linked to increased asthma deaths and worsened symptoms. Limiting its use to as-needed, rather than regular, treatment improved asthma control and reduced mortality.
Area of Science:
- Respiratory Medicine
- Clinical Pharmacology
- Epidemiology
Background:
- A sharp rise in asthma mortality in New Zealand in 1977 prompted an investigation into potential causes.
- Observations suggested a link between frequent beta(2)-agonist use and increased asthma severity and mortality.
Discussion:
- A randomized trial indicated regular fenoterol use worsened asthma control, even with inhaled corticosteroids.
- Case-control studies identified fenoterol prescriptions as a significant risk factor for asthma mortality.
- The withdrawal of fenoterol in New Zealand correlated with dramatic decreases in asthma morbidity and mortality.
Key Insights:
- Evidence suggests fenoterol adversely affects asthma severity and mortality, fulfilling criteria for causality.
- The findings led to modifications in asthma treatment guidelines, advising caution with beta(2)-agonists.
- A significant shift in asthma therapy now recommends only as-needed use of short-acting beta(2)-agonists.
Outlook:
- Further research may explore long-term impacts of different short-acting beta(2)-agonist usage patterns.
- Continued monitoring of asthma morbidity and mortality trends in relation to treatment protocols is essential.
- This study underscores the importance of evidence-based guidelines in managing chronic respiratory diseases.